相关实验视频
Updated: May 12, 2025
07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
7.9K
基因细胞基线激活和早期抑制与花生子语言免疫疗法后的临床结果有关
Jessica R Humphrey1, Rishu Guo2, Xiaohong Yue2
1Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC; Curriculum in Toxicology and Environmental Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.
The Journal of allergy and clinical immunology
|April 17, 2025
概括
在花生下语言免疫疗法 (SLIT) 期间12个月早期抑制基基细胞激活,表明花生过敏儿童的成功缓解. 这种早期标志物可以预测治疗的疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏学 过敏学
- 儿科过敏 儿科过敏
背景情况:
- 语言下免疫疗法 (SLIT) 已证明在诱导幼儿花生过敏的脱敏和缓解方面具有安全性.
- 基细胞激活是一种已知的标记物,由过敏原特异性免疫疗法抑制.
研究的目的:
- 为了评估在花生SLIT期间基细胞抑制的时间.
- 评估基细胞抑制对临床结果和花生过敏缓解的影响.
主要方法:
- 一项随机试验,涉及50名花生过敏儿童,接受花生SLIT或安慰剂36个月.
- 在多个时间点 (基线:12,24,36,39个月) 采集了血液样本,以测量基细胞激活标志物 (CD63,CD203c).
主要成果:
- 花生SLIT显著减少了CD63表达12个月,而安慰剂显示没有变化.
- 在这两组中,CD203c表达保持不变.
- 缓解与较低的基线CD63和12个月的显著抑制有关,与非缓解病例不同.
结论:
- 儿童在12个月内显著抑制基细胞激活,达到缓解,这表明这是花生SLIT疗效的早期指标.
- 在花生过敏中,早期的基细胞抑制可以预测成功的脱敏和长期缓解.
相关概念视频
02:06Allergic Reactions
27.2K
Overview
27.2K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
161
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
161